International Journal of Cardiology
Volume 135, Issue 3 , Pages 338-345 , 10 July 2009

Continuous positive nasal airway pressure decreases levels of serum amyloid A and improves autonomic function in obstructive sleep apnea syndrome

  • Emi Kuramoto

      Affiliations

    • Department of Internal Medicine, Akashi Medical Center, Akashi, Japan
    • Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
    • ,
  • Saori Kinami

      Affiliations

    • Department of Internal Medicine, Akashi Medical Center, Akashi, Japan
    • ,
  • Yoshihiro Ishida

      Affiliations

    • Department of Internal Medicine, Akashi Medical Center, Akashi, Japan
    • ,
  • Hideyuki Shiotani

      Affiliations

    • Faculty of Health Science, Kobe University Graduate School of Medicine, Kobe, Japan
    • ,
  • Yoshihiro Nishimura

      Affiliations

    • Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
    • Corresponding Author InformationCorresponding author. Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. Tel.: +81 78 382 5846; fax: +81 78 382 5859.

Received 1 June 2007 ,Revised 22 October 2007 ,Accepted 30 March 2008.

References 

  1. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001;163:19–25
  2. He J, Kryger MH, Zorick FJ, Conway W, Roth T. Mortality and apnea index in obstructive sleep apnea: experience in 385 male patients. Chest. 1988;94:9–14
  3. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea–hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005;365:1046–1053
  4. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462–466
  5. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease: FRISC Study Group: Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000;343:1139–1147
  6. Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002;105:2019–2023
  7. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation. 2003;107:1129–1134
  8. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165–2168
  9. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103:2531–2534
  10. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis. 2000;148:209–214
  11. Svatikova A, Wolk R, Shamsuzzaman AS, Kara T, Olson EJ, Somers VK. Serum amyloid A in obstructive sleep apnea. Circulation. 2003;108:1451–1454
  12. Kisilevsky R, Tam SP. Acute phase serum amyloid A, cholesterol metabolism, and cardiovascular disease. Pediatr Pathol Mol Med. 2002;21:291–305
  13. Delanghe JR, Langlois MR, De Bacquer D, et al. Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease. Atherosclerosis. 2002;160:471–476
  14. Morrow DA, Rifai N, Antman EM, et al. Serum amyloid A predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol. 2000;35:358–362
  15. Lehmann ED. Clinical value of aortic pulse-wave velocity measurement. Lancet. 1999;354:528–529
  16. Asmar R, Benetos A, Topouchian J, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement: validation and clinical application studies. Hypertension. 1995;26:485–490
  17. Cohn JN. Vascular wall function as a risk marker for cardiovascular disease. J Hypertension. 1999;17:S41–S44
  18. van Popele NM, Grobbee DE, Bots ML, et al. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke. 2001;32:454–460
  19. Narkiewicz K, Montano N, Cogliati C, et al. Altered cardiovascular variability in obstructive sleep apnea. Circulation. 1998;98:1071–1077
  20. Drager LF, Bortolotto LA, Figueiredo AC, et al. Obstructive sleep apnea, hypertension, and their interaction on arterial stiffness and heart remodeling. Chest. 2007;131:1379–1386
  21. Somers VK, Dyken ME, Clary MP, et al. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995;96:1897–1904
  22. Cowan MJ, Burr RL, Narayanan SB, Buzaitis A, Strasser M, Busch S. Comparison of autoregression and fast Fourier transform techniques for power spectral analysis of heart period variability of persons with sudden cardiac arrest before and after therapy to increase heart period variability. J Electrocardiol. 1992;25:234–239
  23. Hartmann G, Tschop M, Fischer R, et al. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine. 2000;12:246–252
  24. Mullington JM, Hinze-Selch D, Pollmacher T. Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions. Ann NY Acad Sci. 2001;933:201–210
  25. Shearer WT, Reuben JM, Mullington JM, et al. Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J Allergy Clin Immunol. 2001;107:165–170
  26. Rogers NL, Szuba MP, Staab JP, Evans DL, Dinges DF. Neuroimmunologic aspects of sleep and sleep loss. Semin Clin Neuropsychiatry. 2001;6:295–307
  27. Kobayashi K, Nishimura Y, Shimada T, et al. Effect of CPAP on soluble CD40 ligand in patients with obstructive sleep apnea syndrome. Chest. 2006;129:632–637
  28. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143
  29. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503–516
  30. Carlson JT, Hedner JA, Sellgren J, et al. Depressed baroreflex sensitivity in patients with obstructive sleep apnea. Am J Respir Crit Care Med. 1996;154:1490–1496
  31. Parati G, Di Rienzo M, Bonsignore MR, et al. Autonomic cardiac regulation in obstructive sleep apnea syndrome: evidence from spontaneous baroreflex analysis during sleep. J Hypertension. 1997;15:1621–1626
  32. Guilleminault C, Connolly S, Winkle R, et al. Cyclical variation of the heart rate in sleep apnoea syndrome. Mechanisms, and usefulness of 24 h electrocardiography as a screening technique. Lancet. 1984;1:126–131
  33. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 1990;172:1535–1545
  34. Doi K, Itoh H, Komatsu Y, et al. Vascular endothelial growth factor suppresses C-type natriuretic peptide secretion. Hypertension. 1996;27:811–815
  35. Schulz R, Hummel C, Heinemann S, et al. Serum levels of vascular endothelial growth factor are elevated in patients with OSAS and severe nighttime hypoxia. Am J Respir Crit Care Med. 2002;165:67–70

PII: S0167-5273(08)00552-4

doi: 10.1016/j.ijcard.2008.03.078

International Journal of Cardiology
Volume 135, Issue 3 , Pages 338-345 , 10 July 2009

Article Tools

* Image Usage & Resolution